Cimetidine in the treatment of porphyria cutanea tarda

被引：15
|
作者：
Horie, Y
Tanaka, K
Okano, J
Ohgi, N
Kawasaki, H
Yamamoto, S
Kondo, M
Sassa, S
机构：
[1] Second Dept. of Internal Medicine, Tottori University, School of Medicine, Yonago
[2] Department of Dermatology, Tottori University, School of Medicine, Yonago
[3] Division of Gastroenterology, Kawasaki Medical School, Kurashiki
[4] Dept. of Nutrition and Biochemistry, Institute of Public Health, Tokyo
[5] Rockefeller University, New York, NY
[6] Second Dept. of Internal Medicine, Tottori University, School of Medicine, Yonago 683
来源：
INTERNAL MEDICINE | 1996年 / 35卷 / 09期
关键词：
cimetidine; porphyria cutanea tarda; uroporphyrin; treatment; porphyria ferritin;
D O I：
10.2169/internalmedicine.35.717
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacy of the H-2 receptor antagonist, cimetidine, in the treatment of a patient with porphyria cutanea tarda (PCT) was evaluated. After administration of cimetidine for 2 weeks, urinary excretion of uroporphyrin (UP) and coproporphyrin (CP) was significantly decreased. Urinary porphyrin levels remained low even after the cessation of cimetidine for 1 week. Although the readministration of cimetidine did not decrease porphyrin excretion, skin lesions were markedly improved, and serum gamma-glutamyl transpeptidase (GGT), aminotransferases and serum ferritin decreased to the normal range. These results suggest that, in addition to efficacy in the treatment of acute intermittent porphyria (AIP) and erythropoietic protoporpyria (EPP), cimetidine is effective in the treatment of PCT.
引用
收藏
页码：717 / 719
页数：3
相关论文
共 50 条
12345